eBC and mBC Treatment | KISQALI® (ribociclib)
KISQALI is a prescription medicine used to treat adults with HR+, HER2- breast cancer. Learn how to get information, support, and access to KISQALI, and see the full prescribing information and side effects.
Kisqali: Uses, Dosage, Side Effects, Warnings - Drugs.com
5 days ago · Kisqali is a prescription medicine for hormone receptor-positive, HER2-negative breast cancer in adults. It blocks CDK4/6 enzymes that regulate cell growth and is used with hormone therapies. Learn about its benefits, risks, and interactions.
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
Sep 17, 2024 · Kisqali (ribociclib) is a CDK4/6 inhibitor that reduces the risk of recurrence by 25% in people with HR+/HER2- stage II and III EBC at high risk of recurrence. The approval is based on the NATALEE trial results and includes patients with node-negative disease.
Kisqali: Dosage, Side Effects, Uses, and More - Healthline
Sep 13, 2023 · Kisqali is a prescription drug for adults with advanced or metastatic breast cancer that is HR-positive and HER2-negative. It works by blocking proteins in cancer cells and is usually taken with...
KISQALI is a kinase inhibitor for hormone receptor-positive, HER2-negative breast cancer. It can interact with CYP3A inhibitors, inducers, and substrates. See full prescribing information for dosage, warnings, and adverse reactions.
Kisqali (ribociclib) dosing, indications, interactions, adverse …
Kisqali is a CDK inhibitor used in combination with aromatase inhibitors or fulvestrant for hormone receptor-positive, HER2-negative breast cancer. Learn about the dosage forms, strengths,...
Kisqali Dosage Guide - Drugs.com
The recommended dosage of KISQALI is 400 mg (two 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off in 28-day treatment cycles. KISQALI should be given in combination with an aromatase inhibitor.
KISQALI is a kinase inhibitor for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. See dosing, administration, warnings, adverse reactions, drug...
How KISQALI® (ribociclib) Works | mBC
KISQALI is a CDK4/6 inhibitor that works with hormone therapy to stop breast cancer cells from growing and spreading. Learn how KISQALI works, its side effects, and its approved use for metastatic breast cancer.
Dosing | mBC | KISQALI® (ribociclib) | HCP
KISQALI is a CDK4/6 inhibitor given orally once daily with an AI or fulvestrant for patients with HR+/HER2- metastatic breast cancer. The recommended starting dose is 600 mg, which can be reduced for hepatic or renal impairment.
- Some results have been removed